Benzinga | Nov 9, 2021 11:41AM EST

Dicerna Pharmaceuticals Q3 EPS $(0.22) Beats $(0.46) Estimate, Sales $62.95M Beat $43.78M Estimate

Dicerna Pharmaceuticals (NASDAQ:DRNA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.46) by 52.17 percent. This is a 24.14 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $62.95 million which beat the analyst consensus estimate of $43.78 million by 43.80 percent. This is a 28.81 percent increase over sales of $48.88 million the same period last year.